Drug Profile


Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Exelixis; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Histiocytosis
  • Phase I/II Solid tumours

Most Recent Events

  • 06 Jun 2017 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA, Australia (PO) (NCT03178851)
  • 01 May 2017 Roche plans the phase III IMspire170 trial for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy, In-operable/Unresectable)
  • 01 Apr 2017 Efficacy and adverse events data from a phase I trial in Solid tumours presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top